Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "**Druggability Assessment:**\n- **Target**: HSP70/HSP90-MAPT interaction modulation\n- **Precedent**: HSP90 inhibitors extensively developed (17-AAG, ganetespib)\n- **Challenge**: Achieving selectivity for tau-associated chaperones\n\n**Existing Chemical Matter:**\n- **HSP90 inhibitors**: 17-AAG, ganetespib, luminespib (multiple failed cancer trials)\n- **HSP70 modulators**: VER-155008, MAL3-101\n- **Protein-protein interaction inhibitors**: Limited success historically\n\n**Development Timeline & Cost:**\n- **6-9 years, $200-400M**\n- Leverage existing HSP modulator knowledge\n- Need novel targeting strategies for selectivity\n\n**Safety Concerns:**\n- HSP inhibition causes broad cellular stress\n- Potential cardiotoxicity (known HSP90 inhibitor issue)\n- Risk of disrupting beneficial chaperone functions\n\n---\n\n### **Hypothesis 7: Tau PTM State Targeting**\n**Drug Development Feasibility: 0.35**\n\n",
  "tokens_used": "222",
  "persona_id": "persona-domain_expert"
}